ASH: Long-term CAR-T data look good for Gilead—but good enough to top its rivals?
admin 11th December 2017 Uncategorised 0Gilead got a boost over the weekend with some positive longer-term data on closely watched CAR-T drug Yescarta. But whether it’s enough to elevate the drug over its competitors remains to be seen.
More: ASH: Long-term CAR-T data look good for Gilead—but good enough to top its rivals?
Source: fierce